NDSN · Q3 2026 Earnings

Bullish

Nordson Corporation

Reported August 19, 2026

30-second summary

30-second take: Nordson printed Q3 revenue of $818M (+10.3% YoY, ~$28M above the top of the prior $760–790M guide) and non-GAAP EPS of $3.25 (+$0.10 above the high end of $2.95–3.15), with organic sales +11.7% and ATS +28.4% carrying broad-based strength across all three segments. Management raised FY2026 revenue guidance to $3.035–3.075B (midpoint +$85M) and FY2026 EPS to $11.80–12.00 (midpoint +$0.35) — the third consecutive raise, and this time the high end moved as aggressively as the low, marking a shift from "de-risking downside" to "committing to upside." Backlog stepped from +18% in Q2 to +35% in Q3, a doubling that gives the raise structural underpinning rather than momentum-chasing.

Headline numbers

EPS

Q3 FY2026

$3.25

Revenue

Q3 FY2026

$0.82B

+10.3% YoY

Gross margin

Q3 FY2026

55.5%

Free cash flow

Q3 FY2026

$0.24B

Operating margin

Q3 FY2026

27.3%

Key financials

Q3 FY2026

Metric	Q3 FY2026	Q3 FY2025	YoY	Q2 FY2026	QoQ
Revenue	$0.82B	$0.74B	+10.3%	$0.74B	+10.4%
EPS	$3.25	$2.73	+19.0%	$2.86	+13.6%
Gross margin	55.5%	54.8%	+70bps	54.5%	+100bps
Operating margin	27.3%	25.3%	+200bps	26.6%	+70bps
Free cash flow	$0.24B	$0.23B	+4.9%	—	—

Guidance

Strong Q3 beat on both revenue and EPS drives full-year FY2026 guidance raise across both metrics.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q3 FY2026	$760M to $790M	$818M	+$28M to +$58M above guide	Beat
EPS (non-GAAP)	Q3 FY2026	$2.95 to $3.15	$3.25	+$0.10 above guide	Beat

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2026	$2,930M to $3,010M	$3,035M to $3,075M	+$25M to +$65M (midpoint +$85M)	Raised
EPS (non-GAAP)	FY2026	$11.30 to $11.80	$11.80 to $12.00	+$0.00 to +$0.20 (midpoint +$0.35)	Raised

Segment KPIs

Q3 FY2026

Segment	Q3 FY2026	Q3 FY2025	YoY
Industrial Precision Solutions	$0.367B	$0.351B	+4.6%
Medical and Fluid Solutions	$0.231B	$0.219B	+5.5%
Advanced Technology Solutions	$0.22B	$0.171B	+28.7%

Other KPIs

Q3 FY2026

Segment	Q3 FY2026	Q3 FY2025	YoY
Americas	$0.331B	$0.315B	+5.1%
Europe	$0.192B	$0.187B	+2.7%
Asia Pacific	$0.294B	$0.24B	+22.5%
Backlog	Up 35% YoY	—	—
EBITDA	$262.5 million, 32% of sales	$239 million	—
Organic Sales Growth	11.7%	2.1%	—
Industrial Precision Solutions EBITDA Margin	35%	—	—
Medical and Fluid Solutions EBITDA Margin	38%	—	—
Advanced Technology Solutions EBITDA Margin	30%	—	—

Management tone

Tone commentary limited: no transcript was available for this quarter; the observations below rely on the press release and prior-quarter framing.

Narrative arc: Q3 FY2025 multi-segment trough call → Q4 FY2025 "headwinds behind us" optimism → Q1 FY2026 numbers validate → Q2 FY2026 momentum accelerates → Q3 FY2026 cycle confirmed with structural demand signal.

The press-release language crossed a threshold this quarter. For three quarters management has been escalating conviction incrementally — "we believe we've troughed" (Q4 FY2025) → "growing confidence" (Q1 FY2026) → "continuing momentum" (Q2 FY2026) → now, in Q3, "delivering above-market organic growth through accelerating demand in key end markets" and "on track to achieve over $3 billion in annual revenue." The $3B milestone framing is the first time in the file management has anchored the narrative to a round-number target rather than a range midpoint; that is a marketing choice with implications. Once management commits publicly to crossing $3B, missing it becomes a materially more visible negative — the fact they made that commitment says they view Q4 execution risk as low.

Backlog language went from validation to amplification. Two quarters ago the +4% Q1 backlog was described as "supportive." Last quarter's +18% was the "step-function jump" that anchored the second raise. This quarter's +35% is a further doubling, and the language moved from "supportive" to the segment-level order strength narrative that Liptak pressed on last quarter (ATS orders "double digits or better than 18% overall"). The +35% figure implies segment-level backlog growth is now running well above the ATS +18% management cited in Q2 Q&A — the demand signal has broadened beyond semiconductor into industrial and medical order flow.

The one thing management did not do this quarter, which prior quarters teased, is announce a scaled M&A transaction. Last quarter's Buscaglia exchange quantified $900M in acquisition capacity; three quarters into FY2026 the only deal that has closed is Capstan AG (a small bolt-on at 9x EBITDA). The press release does not mention M&A activity in Q3. With leverage now well below the long-term target range and FCF conversion above 100% for a fifth consecutive quarter, the capital allocation gap between rhetoric ("robust pipeline") and execution (no deals) is widening. Continued absence of scaled M&A will start to raise the question of whether the pipeline description is accurate or whether the strategic bar is set too high.

Answers to last quarter's watch list

Q3 ATS organic growth against the Q3 FY2025 base of -3.6% YoY — ATS printed +28.4% reported in Q3 with organic growth well above the +8% "clean beat" threshold flagged last quarter. Segment EBITDA margin expanded to 30%, materially above the 27.2% Q2 print and well beyond the 24–25% "normalized" cap management set three quarters ago. This is genuine cycle upside, not comp-driven — the segment is now printing at both higher revenue and higher margin than the framework management provided.

Resolved positively

IPS EBITDA margin holding at or above 35% while inflation flows through — IPS EBITDA margin printed 35%, holding the "margin maintenance" floor management committed to in Q2. Segment revenue grew +4.7% YoY on decelerating FX tailwind, so organic growth is meaningfully improved from prior quarters. Pricing discipline is keeping pace with tariff/component/resin inflation.

Resolved positively

Interventional medical margin walking back toward 38–40% historical range — MFS EBITDA margin printed 38%, up from Q2's 37.1% and squarely inside the 38–40% historical range. Segment revenue grew +5.0%. Management's Q2 framing of the regulatory changeover as "temporary operational inefficiency" is now validated by a full quarter of margin recovery.

Resolved positively

Third consecutive FY guidance raise with low end pulled up more than high end — Yes on the raise (midpoint +$85M revenue / +$0.35 EPS), but the shape shifted: this quarter the entire range moved up, with the new low ends sitting at or above the prior high ends. That is a stronger signal than the "low end raised more" pattern of the prior two quarters — management is no longer just de-risking downside, they are committing to a higher central case.

Resolved positively

Backlog YoY trajectory at +15% or better — Backlog printed +35% YoY, roughly doubling from Q2's +18%. This is materially above the +15% threshold that would confirm the demand signal is structural. The magnitude of the step-up suggests order momentum is broadening beyond the semiconductor/AI concentration that carried Q1 and Q2.

Resolved positively

M&A pipeline conversion — scaled deployment of the $900M acquisition capacity — No scaled M&A was announced this quarter; the press release does not reference any acquisitions closed. Capstan AG remains the only deal in FY2026. The gap between the "robust pipeline" rhetoric and actual deployment is now three quarters wide. With FY organic growth accelerating, the capital allocation debate shifts toward whether buybacks should absorb more of the deployable capital.

Not resolved

FX rolling from H1 tailwind to H2 neutral — implied H2 organic growth has to do more work — Organic sales growth of 11.7% in Q3 accelerated meaningfully from Q2's 6.6%, comfortably absorbing the FX comp shift. Europe decelerated to +3.1% (from Q2's +12.7%), consistent with FX tailwind rolling off; the fact that total organic growth accelerated despite that headwind confirms underlying demand strength.

Resolved positively

What to watch into next quarter

Q4 revenue vs the implied ~$827M at the FY midpoint — with backlog +35% and organic growth accelerating, anything above $860M would represent another clean beat and set up a strong FY2027 setup; anything below $810M would suggest the +35% backlog is not converting on the historical six-month cadence

Whether ATS EBITDA margin holds at 30% or higher — three quarters ago management capped normalized ATS margin at 24–25%; the current 30% print is 500bps above that framework, so any Q4 slip toward 27% would suggest the cycle-peak leverage is starting to compress

IPS organic growth acceleration without FX cover — with H1 FX tailwind now fully rolled off, Q4 IPS reported growth becomes a clean read on underlying industrial demand; anything above +5% would confirm the cycle is broadening into general industrial

M&A execution — a fourth consecutive quarter of "robust pipeline" language with no scaled deal will start to force the market to discount the acquisition capacity claim; alternatively, an announced deal at $200M+ scale would validate the strategic patience

Initial FY2027 revenue and EPS framework on the Q4 print — management typically provides directional FY guidance with the Q4 release; the shape of that first FY2027 guide (relative to the exit-run-rate of Q4 FY2026) will tell you how much of the current cycle strength management believes carries into next year

Backlog trajectory at +25% or better on the Q4 print — a sequential step-down from +35% is expected as record shipments deplete backlog faster than order intake replenishes, but anything below +20% would suggest the momentum peaked in Q3

Buyback pace — with leverage well below the long-term target range, five consecutive quarters of >100% FCF conversion, and M&A execution stalled, the market will want to see repurchases scale up or hear a specific capital return commitment

Sources

Nordson Corporation Q3 FY2026 press release — https://www.sec.gov/Archives/edgar/data/72331/000007233126000052/ndsn-q320268kxex991.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.